These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Brock malignancy risk calculator for pulmonary nodules: validation outside a lung cancer screening population. Chung K; Mets OM; Gerke PK; Jacobs C; den Harder AM; Scholten ET; Prokop M; de Jong PA; van Ginneken B; Schaefer-Prokop CM Thorax; 2018 Sep; 73(9):857-863. PubMed ID: 29777062 [TBL] [Abstract][Full Text] [Related]
4. Development of a Risk Prediction Model to Estimate the Probability of Malignancy in Pulmonary Nodules Being Considered for Biopsy. Reid M; Choi HK; Han X; Wang X; Mukhopadhyay S; Kou L; Ahmad U; Wang X; Mazzone PJ Chest; 2019 Aug; 156(2):367-375. PubMed ID: 30940455 [TBL] [Abstract][Full Text] [Related]
5. Comparing modalities for risk assessment in patients with pulmonary lesions and nondiagnostic bronchoscopy for suspected lung cancer. Yu DH; Shafiq M; Batra H; Johnson M; Griscom B; Chamberlin J; Lofaro LR; Huang J; Bulman WA; Kennedy GC; Yarmus LB; Lee HJ; Feller-Kopman D BMC Pulm Med; 2022 Nov; 22(1):442. PubMed ID: 36434574 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Brock University, Mayo Clinic and Herder models for pretest probability of cancer in solid pulmonary nodules. Susam S; Çinkooğlu A; Ceylan KC; Gürsoy S; Kömürcüoğlu BE; Mertoğlu A; Çırak AK; Gayaf M; Güldaval F; Tuksavul F; Polat G; Ataman S; Yıldırım E; Koparal H; Yücel N Clin Respir J; 2022 Nov; 16(11):740-749. PubMed ID: 36207775 [TBL] [Abstract][Full Text] [Related]
7. [Establishment and Verification of A Novel Predictive Model of Malignancy for Non-solid Pulmonary Nodules]. Xiao F; Yu Q; Zhang Z; Liu D; Liang C Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):26-33. PubMed ID: 30674390 [TBL] [Abstract][Full Text] [Related]
8. Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation. Tanner NT; Porter A; Gould MK; Li XJ; Vachani A; Silvestri GA Chest; 2017 Aug; 152(2):263-270. PubMed ID: 28115167 [TBL] [Abstract][Full Text] [Related]
9. A comparative effectiveness analysis of the PBCG vs. PCPT risks calculators in a multi-ethnic cohort. Carbunaru S; Nettey OS; Gogana P; Helenowski IB; Jovanovic B; Ruden M; Hollowell CMP; Sharifi R; Kittles RA; Schaeffer E; Gann P; Murphy AB BMC Urol; 2019 Nov; 19(1):121. PubMed ID: 31771578 [TBL] [Abstract][Full Text] [Related]
10. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169 [TBL] [Abstract][Full Text] [Related]
11. Communication About the Probability of Cancer in Indeterminate Pulmonary Nodules. Maiga AW; Deppen SA; Massion PP; Callaway-Lane C; Pinkerman R; Dittus RS; Lambright ES; Nesbitt JC; Grogan EL JAMA Surg; 2018 Apr; 153(4):353-357. PubMed ID: 29261826 [TBL] [Abstract][Full Text] [Related]
12. Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population. Foley RW; Lundon DJ; Murphy K; Murphy TB; Galvin DJ; Watson RW Ir J Med Sci; 2015 Sep; 184(3):701-6. PubMed ID: 25843017 [TBL] [Abstract][Full Text] [Related]
13. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284 [TBL] [Abstract][Full Text] [Related]
14. A Structured Program Maximizes Benefit of Lung Cancer Screening in an Area of Endemic Histoplasmosis. Miller JA; Tatakis A; Van Haren RM; Kapur S; Pathrose P; Hemingway M; Starnes SL Ann Thorac Surg; 2022 Jul; 114(1):241-247. PubMed ID: 34339671 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic evaluation of patients with a brain mass as the presenting manifestation of cancer. Mavrakis AN; Halpern EF; Barker FG; Gonzalez RG; Henson JW Neurology; 2005 Sep; 65(6):908-11. PubMed ID: 16186533 [TBL] [Abstract][Full Text] [Related]
16. Prediction of the Risk of Malignancy Among Detected Lung Nodules in the National Lung Screening Trial. Hassannezhad R; Vahed N J Am Coll Radiol; 2018 Nov; 15(11):1529-1535. PubMed ID: 30145120 [TBL] [Abstract][Full Text] [Related]
17. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Cressman S; Peacock SJ; Tammemägi MC; Evans WK; Leighl NB; Goffin JR; Tremblay A; Liu G; Manos D; MacEachern P; Bhatia R; Puksa S; Nicholas G; McWilliams A; Mayo JR; Yee J; English JC; Pataky R; McPherson E; Atkar-Khattra S; Johnston MR; Schmidt H; Shepherd FA; Soghrati K; Amjadi K; Burrowes P; Couture C; Sekhon HS; Yasufuku K; Goss G; Ionescu DN; Hwang DM; Martel S; Sin DD; Tan WC; Urbanski S; Xu Z; Tsao MS; Lam S J Thorac Oncol; 2017 Aug; 12(8):1210-1222. PubMed ID: 28499861 [TBL] [Abstract][Full Text] [Related]
18. The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. van den Bergh RC; Roobol MJ; Wolters T; van Leeuwen PJ; Schröder FH BJU Int; 2008 Nov; 102(9):1068-73. PubMed ID: 18715246 [TBL] [Abstract][Full Text] [Related]
19. Comparison Between Radiological Semantic Features and Lung-RADS in Predicting Malignancy of Screen-Detected Lung Nodules in the National Lung Screening Trial. Li Q; Balagurunathan Y; Liu Y; Qi J; Schabath MB; Ye Z; Gillies RJ Clin Lung Cancer; 2018 Mar; 19(2):148-156.e3. PubMed ID: 29137847 [TBL] [Abstract][Full Text] [Related]